Synthetic strategy and structure-activity relationship (SAR) studies of 3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1, Lificiguat): A review

Ko Hua Yu, Hsin Yi Hung

研究成果: Article同行評審

7 引文 斯高帕斯(Scopus)

摘要

Since 1994, YC-1 (Lificiguat, 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole) has been synthesized, and many targets for special bioactivities have been explored, such as stimulation of platelet-soluble guanylate cyclase, indirect elevation of platelet cGMP levels, and inhibition of hypoxia-inducible factor-1 (HIF-1) and NF-κB. Recently, Riociguat®, the first soluble guanylate cyclase (sGC) stimulator drug used to treat pulmonary hypertension and pulmonary arterial hypertension, was derived from the YC-1 structure. In this review, we aim to highlight the synthesis and structure-activity relationships in the development of YC-1 analogs and their possible indications.

原文English
頁(從 - 到)251-264
頁數14
期刊RSC Advances
12
發行號1
DOIs
出版狀態Published - 2021 12月 20

All Science Journal Classification (ASJC) codes

  • 一般化學
  • 一般化學工程

指紋

深入研究「Synthetic strategy and structure-activity relationship (SAR) studies of 3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1, Lificiguat): A review」主題。共同形成了獨特的指紋。

引用此